Form 4: Intellia Therapeutics CFO Reports Future Share Sale for Tax Obligations

Intellia Therapeutics' EVP and CFO, Edward J. Dulac III, reported a pre-planned mandatory sale of 7,462 common shares at $14.02 each to cover tax withholding obligations related to RSU vesting scheduled for July 2025.

Summary

• Edward J. Dulac III, Executive Vice President and Chief Financial Officer of Intellia Therapeutics, Inc. (NTLA), reported a transaction under a Rule 10b5-1 plan.
• The transaction involves the disposition of 7,462 shares of common stock.
• The shares are scheduled to be sold at a price of $14.02 per share on July 23, 2025.
• This is a mandatory 'sell-to-cover' transaction intended to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs) on July 22, 2025.
• The sale is not a volitional trade by the reporting person, but rather a pre-arranged transaction to meet tax liabilities.
• Following the transaction, Edward J. Dulac III will beneficially own 106,062 shares of common stock.

Sentiment

Score: 5

Explanation: The transaction is a mandatory 'sell-to-cover' for tax purposes upon RSU vesting, which is a routine and non-volitional event for executives and does not reflect a change in management's view of the company's prospects.

Positives

• Vesting of Restricted Stock Units (RSUs) for the EVP, Chief Financial Officer, indicates the realization of equity compensation for the executive.

Negatives

• No direct negatives identified as the sale is non-volitional and for tax purposes, not indicative of a lack of confidence in the company.

Risks

• NA

Future Outlook

NA

Management Comments

• "Represents a mandatory 'sell-to-cover' transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on July 22, 2025, and does not represent a volitional trade by the Reporting Person."

Industry Context

This is a routine insider transaction for tax purposes, common across all industries for executives receiving equity compensation, and does not provide specific industry-wide insights.

Comparison to Industry Standards

• The 'sell-to-cover' transaction is a standard practice for executives in publicly traded companies globally when Restricted Stock Units (RSUs) vest, as it allows them to meet tax obligations without needing to use personal funds. This type of transaction is common across various sectors, including biotechnology, and is not indicative of company-specific performance issues or management sentiment, unlike volitional sales.

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• Sale of 7,462 common shares by EVP, Chief Financial Officer Edward J. Dulac III to satisfy tax withholding obligations related to RSU vesting, a transaction between an insider and the company's equity.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a non-volitional, tax-related sale, not signaling a lack of confidence from management.
• Employees: Reflects standard equity compensation practices for executives, indicating the realization of vested equity.

Next Steps

• NA

Key Dates

Recommendation

The reported transaction is a mandatory 'sell-to-cover' to satisfy tax obligations upon the vesting of Restricted Stock Units (RSUs) and is not a volitional trade. As such, it does not reflect management's sentiment regarding the company's future performance or stock value, and therefore, does not warrant a change in investment recommendation based solely on this filing.

Keywords

Intellia Therapeutics, NTLA, Form 4, Insider Trading, Stock Sale, CFO, Edward J. Dulac III, Sell-to-cover, RSU, Restricted Stock Units, Tax Withholding, 10b5-1 Plan